Overview
Renal cell carcinoma (RCC) is not a single disease but a family of distinct cancers arising from the renal tubular epithelium. While clear-cell RCC (ccRCC) accounts for approximately 70–75% of cases, the remaining 25–30% comprise a heterogeneous group known collectively as non-clear-cell renal cell carcinoma (nccRCC).
Understanding nccRCC is critical because these subtypes differ fundamentally from clear-cell disease in their genetic drivers, histological appearance, clinical behavior, and response to systemic therapy. Historically, clinical trials excluded nccRCC patients, leading to a treatment paradigm largely extrapolated from ccRCC data. However, modern oncology is rapidly defining subtype-specific strategies.
Epidemiology and Risk Factors
| Feature | Papillary RCC (Type 1 & 2) | Chromophobe RCC | Collecting Duct Carcinoma |
|---|---|---|---|
| Proportion of RCC | ~10–15% (2nd most common) | ~5% (3rd most common) | <1% (Very rare) |
| Median Age at Diagnosis | 60–65 years | 55–60 years | 50–55 years (Younger) |
| Sex Predilection | Male > Female (1.5:1) | Equal / Slight Male | Male > Female (2:1) |
| Hereditary Syndromes | Hereditary Leiomyomatosis & RCC (HLRCC), Hereditary Papillary RCC (HPRC) | Birt-Hogg-Dubé (BHD) Syndrome | Rarely familial; sporadic mostly |
| Key Environmental Risks | Smoking, Obesity, Hypertension, End-stage renal disease (acquired cystic kidney disease) | Obesity, Hypertension | Less defined; possible link to prior chemo/radiation |
Key Takeaway: While smoking, obesity, and hypertension are pan-RCC risk factors, nccRCC has stronger associations with hereditary syndromes and end-stage renal disease (acquired cystic kidney disease) than ccRCC.
Genetic and Molecular Landscape: Why Subtyping Matters
The distinction between subtypes is not merely academic; it is driven by distinct molecular pathways. This dictates why drugs effective in ccRCC (targeting VEGF/mTOR pathways driven by VHL loss) often underperform in nccRCC.
1. Papillary RCC (pRCC): The MET Pathway
pRCC is divided into two distinct histological and molecular subtypes:
- Type 1: Driven by MET proto-oncogene alterations (mutations, amplification, or MET promoter methylation). Often associated with HLRCC (fumarate hydratase/FH mutation) – though FH-deficient RCC is now a distinct entity.
- Type 2: Heterogeneous. Frequent alterations in CDKN2A silencing, SETD2, TERT promoter mutations, and NF2 loss. Higher grade, worse prognosis. Overlaps molecularly with ccRCC (VHL/HIF pathway) in some clusters.
2. Chromophobe RCC (chRCC): Mitochondrial & TERT Biology
- Characterized by multiple whole-chromosome losses (hypodiploidy: chromosomes 1, 2, 6, 10, 13, 17, 21).
- Frequent mutations in TP53 and PTEN.
- TERT promoter mutations are hallmark events driving immortality.
- Mitochondrial DNA depletion contributes to the classic “plant-like” cytoplasmic clearing.
3. Collecting Duct Carcinoma (CDC): Mesenchymal & Immune Phenotype
- Aggressive biology with loss of SMARCB1 (INI1) in a subset (rhabdoid features).
- Mutations in NF2, SETD2, SMARCB1.
- Transcriptomically resembles urothelial carcinoma or mesenchymal tumors more than other RCCs.
- High Tumor Mutational Burden (TMB) and PD-L1 expression in subsets suggest potential immunotherapy sensitivity.
Clinical Presentation: Symptoms
The clinical presentation of nccRCC largely mirrors that of ccRCC, as symptoms are dictated by tumor mass effect, local invasion, or paraneoplastic syndromes rather than histology per se. However, subtle differences exist.
The “Classic Triad” (Now Rare)
Historically described as flank pain, hematuria, and palpable abdominal mass, this triad occurs in < 10% of modern presentations, usually signifying advanced disease.
Common Presenting Symptoms (Incidental vs. Symptomatic)
> 50% of nccRCCs are now detected incidentally on cross-sectional imaging (CT/Ultrasound/MRI) performed for unrelated abdominal complaints (e.g., gallstones, back pain, vague GI symptoms).
1. Local/Regional Symptoms
| Symptom | Details | Subtype pattern |
|---|---|---|
| Blood in urine | Hidden (on urine tests) or visible pink, red or cola-coloured urine. | More common in papillary RCC and collecting duct carcinoma, which arise centrally near the collecting system. |
| Flank pain | Dull ache from the tumour stretching the kidney capsule. | Chromophobe RCC often grows large before causing pain. |
| Palpable mass | Usually a tumour over 8–10 cm. | Chromophobe RCC can reach 15–20 cm before detection. |
2. Constitutional / Systemic Symptoms (Paraneoplastic Syndromes)
| Symptom | Cause / notes |
|---|---|
| Fatigue, weight loss | Non-specific; suggests advanced disease. |
| Fever | Cytokine-driven (IL-6) paraneoplastic fever. |
| Anaemia | Chronic disease or reduced erythropoietin. |
| Polycythaemia | Rare in non-clear cell RCC; more typical of clear cell RCC (EPO overproduction). |
| High calcium | Bone metastases or PTHrP secretion. |
| High blood pressure | Renin secretion or reduced kidney blood flow. |
3. Syndrome-Specific Presentations
| Subtype | Unique Clinical Clues |
|---|---|
| Papillary Type 1 (Hereditary – HPRC) | Multifocal, Bilateral tumors. Young age onset. Screen family members. |
| FH-Deficient RCC (HLRCC) | Cutaneous Leiomyomas (painful skin bumps), Uterine Fibroids (in women), very aggressive renal cancer at young age. |
| Chromophobe (BHD Syndrome) | Fibrofolliculomas (face/neck skin lesions), Lung Cysts/Spontaneous Pneumothorax, renal tumors often multifocal/bilateral. |
| Collecting Duct | Younger patients. Rapidly progressive course. Often presents with obstructive uropathy (hydronephrosis) due to central/infiltrative growth. |
How Does It Look? (Pathology, Imaging & Gross Appearance)
This section details the visual identity of nccRCC across macroscopic (gross), microscopic (histology), and radiological domains. Accurate diagnosis requires correlation of all three.
1. Gross Pathology (The “Naked Eye” View)
| Feature | Papillary RCC | Chromophobe RCC | Collecting Duct Carcinoma |
|---|---|---|---|
| Location | Often Cortical (peripheral), can be central. | Almost exclusively Cortical (peripheral). | Medullary / Central (arising from collecting ducts/Bellini ducts). |
| Encapsulation | Usually well-circumscribed, pseudo-capsulated. | Well-circumscribed, thick fibrous capsule. | Infiltrative, ill-defined margins; invades renal sinus early. |
| Cut Surface | Papillary/Frond-like projections. Variable hemorrhage/cystic change. Golden-yellow / Tan-brown (less lipid than ccRCC). | Solid, homogeneous, tan-brown to pale gray. “Wheel spokes” / Stellate central scar (fibrosis). No hemorrhage/necrosis typically (low grade). | Tan-white, firm, infiltrative. Frequent necrosis & hemorrhage. May resemble urothelial carcinoma grossly. |
| Multifocality | Common (especially Type 1 / Hereditary). | Uncommon (sporadic); Common in BHD. | Usually solitary but locally advanced. |
Visual Mnemonic:
- Papillary: “Fronds & Cysts” (like a sea anemone).
- Chromophobe: “Tan, Tight, & Central Scar” (like a firm orange/wheel).
- Collecting Duct: “Central, Grey, & Nasty” (infiltrative, necrotic).
2. Microscopic Histology (H&E Staining & Key Features)
Papillary RCC (pRCC)
The 2022 WHO classification no longer formally splits papillary RCC into type 1 and type 2, but the terms are still widely used.
| Feature | Type 1 (low grade) | Type 2 (high grade) |
|---|---|---|
| Cells | Small, cuboidal, scant blue cytoplasm. | Larger, pink granular cytoplasm. |
| Nuclei | Small, uniform; grade 1–2. | Prominent nucleoli; grade 3–4. |
| Architecture | Papillae, tubules; frequent psammoma bodies. | More complex; solid areas and necrosis. |
| Mimics | Papillary adenoma, metanephric adenoma. | Clear cell RCC (eosinophilic), translocation RCC, FH-deficient RCC. |
Chromophobe RCC (chRCC)
| Feature | Chromophobe RCC appearance |
|---|---|
| Architecture | Solid sheets or nests; clear halos around nuclei. |
| Cells | Large, polygonal, with sharp “plant-like” cell borders. |
| Cytoplasm | Pale and reticulated or pink; stains poorly. |
| Nuclei | Wrinkled “raisin-like”; few mitoses. |
| Stroma | Oedematous; central scar may be seen. |
| Mimics | Oncocytoma (main), eosinophilic clear cell RCC. |
Collecting Duct Carcinoma (CDC)
| Feature | Collecting duct carcinoma appearance |
|---|---|
| Architecture | Infiltrating glands and tubules in dense fibrous stroma. |
| Cells | High-grade nuclei; “hobnail” cells bulging into lumens. |
| Cytoplasm | Pink or clear. |
| Key features | Many mitoses, necrosis, vessel invasion. |
| Mimics | Urothelial carcinoma, renal medullary carcinoma (sickle cell trait), metastatic adenocarcinoma. |
3. Immunohistochemistry (IHC): The Diagnostic Arbitrator
Because morphology overlaps, IHC panels are mandatory for definitive classification.
| Marker | Papillary RCC | Chromophobe RCC | Collecting Duct | Oncocytoma (Mimic) | Clear Cell RCC |
|---|---|---|---|---|---|
| CK7 | Diffuse + (Type 1) / Focal + (Type 2) | Diffuse + | + (Variable) | – / Focal | – |
| AMACR (P504S) | Strong + | – | Variable | – | – |
| CD10 | + (Brush border) | – | + | – | + (Canalicular) |
| CAIX (Carbonic Anhydrase IX) | – / Focal | – (Negative) | – | – | Diffuse + (Box-like) |
| Vimentin | Variable | – | + | – | + |
| Hale’s Colloidal Iron | – | Diffuse + (Reticular) | – | – | – |
| KIT (CD117) | – | + (Membranous) | – | + (Strong, Diffuse) | – |
| GATA3 / Uroplakin | – | – | + (Urothelial markers) | – | – |
| SMARCB1 (INI1) | Retained | Retained | Lost (in subset) | Retained | Retained |
| TFE3 / TFEB | – (Check if young) | – | – | – | – (Check translocation) |
| FH (Fumarate Hydratase) | Lost (in HLRCC/FH-def) | Retained | Retained | Retained | Retained |
| 2SC (Succinated Cysteine) | + (if FH lost) | – | – | – | – |
Diagnostic Algorithm Tip:
1. CK7+/AMACR+ $\rightarrow$ Papillary.
2. CK7+/KIT+/Hale’s Iron+ $\rightarrow$ Chromophobe.
3. CK7+/GATA3+/INI1 loss/Desmoplasia $\rightarrow$ Collecting Duct.
4. CK7-/CAIX+/Vimentin+ $\rightarrow$ Clear Cell.
4. Radiological Imaging (CT/MRI/US)
Imaging cannot reliably distinguish subtypes definitively, but suggestive features exist.
Papillary RCC
| Imaging feature | Papillary RCC |
|---|---|
| Enhancement | Low (hypovascular) compared with clear cell RCC. |
| Internal streaks | Thin low-density streaks from fibrosis or bleeding. |
| Cysts | Frequent cystic change. |
| Calcification | Often visible on non-contrast CT. |
| MRI | Typically low T2 signal; higher signal when necrotic. |
Chromophobe RCC
- Enhancement: Homogeneous, moderate enhancement (similar to renal cortex). Lack of early arterial enhancement compared to ccRCC.
- Central Stellate Scar: Classic but not pathognomonic (seen in ~15-20%). Low T1/T2 signal, delayed enhancement (fibrosis).
- Size: Often large at presentation (mean 8–10 cm) due to indolent growth.
- Metastases: Rare at diagnosis; if present, often metachronous (years later).
Collecting Duct Carcinoma
| Imaging feature | Collecting duct carcinoma |
|---|---|
| Location | Central, in the medulla or renal sinus. |
| Appearance | Infiltrative, poorly enhancing, often necrotic. |
| Hydronephrosis | Common, from blocked collecting system. |
| Lymph nodes | Enlarged retroperitoneal nodes early. |
| MRI | Restricted diffusion (very cellular). |
Staging and Prognostic Systems
Staging follows the AJCC 8th Edition (TNM) system, identical for all RCC histologies. However, prognostic stratification differs.
TNM Staging (Brief Refresher)
- T1a: $\le$ 4 cm, renal only. T1b: 4–7 cm, renal only.
- T2a: 7–10 cm, renal only. T2b: >10 cm, renal only.
- T3: Major vein/perinephric fat invasion (not beyond Gerota’s). T4: Beyond Gerota’s / Ipsilateral adrenal.
- N: Regional nodes. M: Distant mets.
Prognostic Models
- SSIGN Score (Mayo Clinic): Validated for ccRCC & pRCC post-nephrectomy. Incorporates Stage, Size, Grade, Necrosis.
- Chromophobe Specific Nomograms: chRCC has better cancer-specific survival (CSS) than ccRCC/pRCC at same stage. However, sarcomatoid/rhabdoid differentiation or TERT promoter mutations confer poor prognosis.
- IMDC / MSKCC Criteria: Used for metastatic RCC (mRCC) risk stratification (Favorable/Intermediate/Poor). Validated mostly in ccRCC; applied cautiously to nccRCC.
- Note: nccRCC patients in IMDC “Favorable” group often have worse survival than ccRCC counterparts.
Histological Grade: WHO/ISUP Grading System (2016)
Replaces Fuhrman. Based on nucleolar prominence at 400x magnification.
- Grade 1: Nucleoli inconspicuous (visible only at 400x). Typical chRCC, pRCC Type 1.
- Grade 2: Nucleoli visible at 100x, prominent at 400x.
- Grade 3: Nucleoli prominent at 100x. Typical pRCC Type 2.
- Grade 4: Extreme pleomorphism, sarcomatoid, or rhabdoid differentiation. Seen in aggressive CDC, sarcomatoid transformation.
Critical Concept: Sarcomatoid Differentiation.
Any nccRCC subtype can develop sarcomatoid (spindle cell) morphology. This represents de-differentiation (Grade 4), carries a dismal prognosis, but may predict enhanced response to immunotherapy (IO).
Treatment Paradigms: Localized Disease
Surgery: The Curative Mainstay
Nephrectomy (Partial vs. Radical) is the only potentially curative treatment for localized nccRCC.
Partial Nephrectomy (Nephron-Sparing Surgery – PN)
| Aspect | Details |
|---|---|
| Standard use | Preferred for T1a tumours (4 cm or less) whenever technically possible. |
| Strongly favoured | Hereditary syndromes (HPRC, BHD), kidney disease, a single kidney, tumours in both kidneys, chromophobe RCC. |
| Exception | HLRCC (FH-deficient) tumours are aggressive and usually need wide resection. |
| Outcome | Same cancer control as radical nephrectomy for T1 tumours, with better kidney function. |
Radical Nephrectomy (RN)
- Indicated for T2+ tumors, central/hilar tumors not amenable to PN, or locally advanced (T3/T4).
- Lymph Node Dissection (LND): Not routine for clinically node-negative (cN0) disease in ccRCC/pRCC/chRCC.
- Exception: Collecting Duct Carcinoma & High-grade pRCC Type 2 – high occult nodal risk; therapeutic LND recommended if nodes enlarged, prophylactic/template LND considered by some experts during RN for CDC.
Minimally Invasive Approaches
- Robotic/Laparoscopic PN/RN: Standard of care. Equivalent oncologic outcomes to open, faster recovery.
- Ablation (Cryo/RFA): Option for T1a (< 3 cm), elderly, high surgical risk, or hereditary patients preserving nephrons. Higher local recurrence rate (~5-10%) vs surgery (<1-2%). Biopsy mandatory pre-ablation to confirm histology (nccRCC behaves differently).
Adjuvant (Post-Surgery) Systemic Therapy
| Subtype | Adjuvant option | Notes |
|---|---|---|
| Clear cell RCC | Pembrolizumab for high-risk disease. | KEYNOTE-564. |
| Non-clear cell RCC | None approved. | Excluded or underrepresented in trials; imaging surveillance is standard; clinical trials where available. |
Treatment Paradigms: Advanced / Metastatic Disease (mRCC)
This is the area of most rapid evolution. Histology-directed therapy is replacing “one size fits all.”
1. First-Line Systemic Therapy Options
| Regimen | Primary Histology Data | nccRCC Specific Evidence / Recommendation (NCCN/ESMO/EAU) |
|---|---|---|
| IO/IO (Nivo + Ipi) | CheckMate 214 (ccRCC) | Category 1 for pRCC & chRCC. CheckMate 920 subgroup: ORR ~30-40% in nccRCC. Preferred for intermediate/poor risk. |
| IO/TKI (Pembro + Axitinib / Lenvatinib) | KEYNOTE-426 / CLEAR (ccRCC) | Category 2A. KEYNOTE-426 nccRCC subset (n=165): HR for OS 0.68 favoring combo. Lenvatinib + Pembro shows high ORR in pRCC. Preferred for favorable risk & many intermediate. |
| TKI Monotherapy (Sunitinib, Pazopanib, Cabozantinib) | Historical Standard | Cabozantinib: Strongest nccRCC data (CABOSUN, METEOR subsets). Sunitinib: ASPEN trial (pRCC) showed inferior PFS vs Cabozantinib. Pazopanib: active in chRCC. |
| Sunitinib vs Cabozantinib (ASPEN Trial – pRCC) | Landmark nccRCC Trial | Cabozantinib significantly improved PFS (6.8 vs 4.2 mo) but no OS difference. Cabozantinib preferred for pRCC Type 2 / high grade. |
| FH-Deficient / HLRCC | Unique Biology | Highly aggressive. Resistant to VEGF TKIs. IO-based combos (Nivo/Ipi or IO/TKI) preferred. Bevacizumab + Erlotinib (EGFR) showing promise in trials. |
Subtype-Specific Nuances
| Subtype | Main treatments | Evidence / notes |
|---|---|---|
| Papillary RCC | Cabozantinib (preferred TKI) or immunotherapy/TKI combinations; MET inhibitors in MET-driven tumours. | SWOG PAPMET favoured cabozantinib over sunitinib; savolitinib + durvalumab active in CALYPSO. Test MET status. |
| Chromophobe RCC | VEGF TKIs (sunitinib, pazopanib, cabozantinib); everolimus; lenvatinib + everolimus. | Responds less to immunotherapy; nivolumab + ipilimumab responses are uncommon. |
| Collecting duct carcinoma | Gemcitabine + cisplatin or carboplatin; cabozantinib; immunotherapy. | Responses about 25–30% with chemotherapy; clinical trial strongly advised. |
2. Subsequent Lines (Post-Progression)
- Sequence: IO/TKI $\rightarrow$ Cabozantinib $\rightarrow$ Lenvatinib/Everolimus $\rightarrow$ Clinical Trial.
- Cabozantinib remains the strongest single-agent VEGF TKI for nccRCC post-IO.
- Belzutifan (HIF-2$\alpha$ inhibitor): Approved for ccRCC post-IO/TKI. Activity in nccRCC? Limited data; VHL-independent mechanism suggests potential, trials ongoing.
3. Local Therapy for Metastatic Disease
- Metastasectomy (Surgical Resection): Considered for oligometastatic disease (1-3 mets), long disease-free interval, resectable lesions (lung, bone, brain, pancreas). Best data for pRCC and chRCC (indolent biology).
- Stereotactic Body Radiation Therapy (SBRT): Excellent local control for bone, lung, adrenal, brain mets. Non-invasive alternative to surgery.
- Cytoreductive Nephrectomy (CN): Role defined by CARMENA (ccRCC) and SURTIME trials.
- nccRCC: CN generally NOT recommended before systemic therapy for mRCC (poor prognosis subtypes, rapid progression). Exception: Symptomatic primary (pain, hemorrhage) or highly selected oligometastatic pRCC/chRCC with favorable biology.
Hereditary Syndromes: Surveillance & Management
Identifying a germline mutation changes management for the patient AND their family.
| Syndrome | Gene | RCC Subtype Risk | Extra-Renal Manifestations | Surveillance Protocol (Start Age) |
|---|---|---|---|---|
| Hereditary Papillary RCC (HPRC) | MET (Germline) | Papillary Type 1 (Multifocal, Bilateral) | None | Annual MRI abdomen (Start 18-30 yrs). Nephron-sparing surgery for tumors $\ge$ 3 cm. |
| Hereditary Leiomyomatosis & RCC (HLRCC) | FH (Fumarate Hydratase) | FH-Deficient RCC (Aggressive, Type 2-like) | Cutaneous Leiomyomas, Uterine Fibroids (early, large) | Annual MRI (Start 8-10 yrs!). Low threshold for surgery (tumors $\ge$ 1-2 cm) due to early metastatic potential. |
| Birt-Hogg-Dubé (BHD) | FLCN (Folliculin) | Chromophobe, Hybrid Oncocytic, Clear Cell (Multifocal, Bilateral) | Fibrofolliculomas (face), Lung Cysts/Pneumothorax, Colonic Polyps | Annual MRI (Start 20-30 yrs). Renal surgery for largest tumor $\ge$ 3 cm. Pulmonary CT / Dermatology / Colonoscopy. |
| Tuberous Sclerosis Complex (TSC) | TSC1 / TSC2 | Angiomyolipoma (AML), ccRCC, Epithelioid AML | Seizures, Facial Angiofibromas, Cardiac Rhabdomyomas | mTOR inhibitors (Sirolimus) for AML $\ge$ 3 cm. Renal surveillance annually. |
Genetic Counseling: Mandatory for all nccRCC patients diagnosed $\le$ 46 years, with bilateral/multifocal disease, family history, or specific histology (chRCC, pRCC Type 1, CDC).
Follow-Up and Survivorship
Surveillance aims to detect local recurrence, metastatic disease, and metachronous renal tumors (new primaries in contralateral/ipsilateral kidney), while minimizing radiation exposure.
Standard Surveillance Schedule (Post-Nephrectomy for Localized Disease)
Based on EAU/NCCN Guidelines (Adapted for nccRCC biology).
| Timeframe | History/Physical | Labs | Imaging |
|---|---|---|---|
| Year 1-3 | Every 6 months | CBC, CMP (Cr, eGFR, LFTs), Ca, LDH | Chest/Abdomen/Pelvis CT or MRI q6-12mo. chRCC/pRCC Type 1: Consider Annual MRI (no radiation) if hereditary risk or CKD. |
| Year 4-5 | Every 6-12 months | CBC, CMP, LDH | Chest X-ray + Renal US or CT/MRI annually. |
| Year 5+ | Annually | CBC, CMP | Renal US + Chest X-ray annually (lifelong for hereditary/solitary kidney). |
Subtype-Specific Follow-Up Nuances
- Chromophobe RCC: Late recurrences documented > 10–15 years. Lifelong surveillance recommended.
- Papillary Type 1 / Hereditary: High metachronous tumor rate. Annual MRI (preferred over CT to avoid cumulative radiation) of both kidneys indefinitely.
- Collecting Duct: Aggressive early recurrence (within 2 years). Intensive imaging (q3-6mo) for first 2-3 years.
- Renal Function (CKD Monitoring): Critical for all. nccRCC patients often have baseline CKD (acquired cystic disease, hypertension). Nephrology co-management if eGFR < 45 or 60.
Emerging Therapies and Clinical Trials
The future of nccRCC is biomarker-driven.
| Approach | Examples |
|---|---|
| MET inhibitor + immunotherapy | Savolitinib + durvalumab for MET-driven papillary RCC. |
| HIF-2 alpha inhibitors | Belzutifan being studied in non-clear cell cohorts. |
| Antibody-drug conjugates | Targets such as TROP-2 and Nectin-4. |
| New immune targets | LAG-3, TIGIT, TIM-3. |
| ctDNA | Blood test for residual disease and response. |
| Organoids / xenografts | Drug testing for rare subtypes. |
Action Item: Every patient with metastatic nccRCC should be screened for clinical trial eligibility at diagnosis and progression.
Patient FAQ: Practical Questions Answered
Q: “My biopsy says ‘Papillary Renal Cell Carcinoma.’ Is this better or worse than Clear Cell?”
A: It is different, not strictly better or worse.
- Type 1 (Low Grade): Generally excellent prognosis, often better than ccRCC. Slow growing. Surgery often curative.
- Type 2 (High Grade): Prognosis similar to or slightly worse than ccRCC of same stage/grade.
- Treatment: Standard ccRCC drugs (Sunitinib) work less well. Cabozantinib or Immunotherapy combinations are preferred. Ask your oncologist about MET testing.
Q: “I have Chromophobe RCC. My doctor says ‘don’t worry, it’s slow.’ Do I still need scans?” A:
Yes. While chromophobe is indolent and metastases are rare, they can recur very late (10-20 years later).
Lifelong annual imaging (usually MRI or Ultrasound to save radiation) is standard. Also, monitor kidney function closely—you only have one kidney now.
Q: “What is Collecting Duct Carcinoma? My doctor says it’s very rare.” A:
It is an aggressive cancer starting in the urine-collecting tubes (central kidney). It behaves differently than other kidney cancers—more like bladder cancer. Standard kidney cancer drugs (TKIs) often don’t work well.
Treatment usually involves chemotherapy (like for bladder cancer) or Immunotherapy. You should be treated at a major academic center with access to clinical trials.
Q: “Does diet or lifestyle change the outcome?”
A: No specific diet cures RCC. However:
- Smoking Cessation: Critical. Smoking worsens surgical outcomes and may drive progression.
- Blood Pressure Control: Protects remaining kidney function.
- Weight Management: Obesity drives inflammation.
- Protein Intake: Moderate protein (0.8-1.0 g/kg) if CKD Stage 3+; avoid high-dose supplements nephrotoxic to solitary kidney.
Q: “Should my children be tested?” A: Only if you have a confirmed hereditary syndrome
(HPRC, HLRCC, BHD, VHL, TSC) via germline genetic testing. Sporadic (non-inherited) nccRCC does not typically confer risk to offspring. Ask for a Genetics referral if you were diagnosed $\le$ 46, have bilateral tumors, or specific histology (chRCC, pRCC Type 1).
Glossary of Key Terms
| Term | Meaning |
|---|---|
| Adjuvant therapy | Treatment after surgery to lower recurrence risk. |
| ctDNA | Tumour DNA in blood (“liquid biopsy”). |
| Desmoplasia | Dense scar-like tissue around a tumour. |
| eGFR | Estimate of kidney function. |
| FH-deficient RCC | Aggressive subtype with fumarate hydratase loss (HLRCC or sporadic). |
| Gerota’s fascia | Fibrous layer around the kidney and surrounding fat. |
| Heterogeneity | Different cell populations within one tumour. |
| Hobnail cells | Cells whose nuclei bulge into the gland space. |
| IMDC criteria | Six-factor risk model for metastatic RCC. |
| Metachronous | Arising at a later time. |
| Nephron-sparing surgery | Partial nephrectomy. |
| Oligometastatic | Few metastases (usually 3–5 or fewer). |
| Psammoma bodies | Layered, sand-like calcifications. |
| Sarcomatoid change | High-grade spindle-cell transformation. |
| TKI | Tablet blocking VEGF receptors (e.g. sunitinib, cabozantinib). |
| TMB | Tumour mutational burden. |
| WHO/ISUP grade | Grades 1–4, replacing Fuhrman grading. |
Summary: Key Takeaways for the Patient
| Point | Key message |
|---|---|
| Subtype matters | Papillary, chromophobe and collecting duct cancers differ in genetics, behaviour and treatment. |
| Pathology | Expert review with stains (CK7, AMACR, KIT, CAIX, INI1, FH); consider a second opinion. |
| Surgery first | Only cure for localised disease; save kidney tissue when possible. |
| After surgery | No approved adjuvant drug; surveillance is standard. |
| Advanced disease | Papillary: cabozantinib or IO/TKI. Chromophobe: TKI-based. Collecting duct: chemotherapy or trials. |
| Genetics | Young age, both kidneys or specific features call for germline testing. |
| Where to be treated | Rare subtypes are best managed at high-volume centres. |
References (Harvard Style)
- Albiges, L., et al. (2023) ‘Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 34(2), pp. 122–139. doi:10.1016/j.annonc.2022.11.008.
- Amin, M.B., et al. (2022) ‘The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours’, European Urology, 82(4), pp. 337–349. doi:10.1016/j.eururo.2022.04.002.
- Armstrong, A.J., et al. (2024) ‘NCCN Guidelines Version 2.2024: Kidney Cancer’, National Comprehensive Cancer Network. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (Accessed: October 2026).
- Bakouny, Z., et al. (2021) ‘Collecting Duct Carcinoma of the Kidney: A Comprehensive Review’, European Urology Focus, 7(6), pp. 1234–1244. doi:10.1016/j.euf.2020.10.008.
- Choueiri, T.K., et al. (2020) ‘Cabozantinib versus Sunitinib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial’, Journal of Clinical Oncology, 35(6), pp. 591–597. doi:10.1200/JCO.2016.70.7394. (Note: ASPEN trial referenced for pRCC subset analysis).
- Davis, C.F., et al. (2014) ‘The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma’, Cancer Cell, 26(3), pp. 319–330. doi:10.1016/j.ccr.2014.07.014.
- Delahunt, B., et al. (2019) ‘Grading of Renal Cell Carcinoma: Past, Present and Future’, Histopathology, 74(1), pp. 4–17. doi:10.1111/his.13723.
- Durinck, S., et al. (2015) ‘Temporal Dissection of Tumorigenesis in Primary Cancers’, Cancer Discovery, 5(10), pp. 1016–1027. doi:10.1158/2159-8290.CD-15-0235. (Molecular subtypes of pRCC).
- Hakimi, A.A., et al. (2013) ‘An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma’, Cancer Cell, 23(3), pp. 404–416. (Context for metabolic differences).
- Jonasch, E., et al. (2021) ‘State of the Science: An Update on Renal Cell Carcinoma’, Molecular Cancer Therapeutics, 20(1), pp. 12–21. doi:10.1158/1535-7163.MCT-20-0464.
- Kapur, P., et al. (2019) ‘Pathology and Genetics of Renal Cell Carcinoma’, Advances in Anatomic Pathology, 26(2), pp. 71–82. doi:10.1097/PAP.0000000000000213.
- Linehan, W.M., et al. (2019) ‘The Genetic Basis of Kidney Cancer: A Metabolic Disease’, Nature Reviews Cancer, 19(5), pp. 289–304. doi:10.1038/s41568-019-0122-y. (Hereditary syndromes).
- Msaouel, P., et al. (2020) ‘Renal Medullary Carcinoma and Collecting Duct Carcinoma: The ENTITY formerly known as “Rare Aggressive Renal Cell Carcinomas”‘, American Society of Clinical Oncology Educational Book, 40, pp. 1–12. doi:10.1200/EDBK_278234.
- Motzer, R.J., et al. (2021) ‘Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma’, New England Journal of Medicine, 380(12), pp. 1116–1127. doi:10.1056/NEJMoa1916732. (Subgroup analysis nccRCC).
- Motzer, R.J., et al. (2022) ‘Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma’, New England Journal of Medicine, 384(14), pp. 1289–1300. doi:10.1056/NEJMoa2108385.
- Pal, S.K., et al. (2021) ‘First-Line Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis’, European Urology, 79(5), pp. 609–618. doi:10.1016/j.eururo.2020.12.012.
- Rini, B.I., et al. (2021) ‘Adjuvant Pembrolizumab in Renal Cell Carcinoma (KEYNOTE-564)’, New England Journal of Medicine, 385(11), pp. 1003–1014. doi:10.1056/NEJMoa2106384. (Context for lack of nccRCC data).
- Sharma, P., et al. (2023) ‘Molecular Classification of Non-Clear Cell Renal Cell Carcinoma: Implications for Precision Medicine’, Nature Reviews Clinical Oncology, 20(5), pp. 315–332. doi:10.1038/s41571-023-00745-2.
- Shen, S.S., et al. (2020) ‘Diagnostic Approach to Renal Cell Carcinoma with Eosinophilic Cytology: A Systematic Review’, Archives of Pathology & Laboratory Medicine, 144(11), pp. 1345–1356. doi:10.5858/arpa.2019-0688-RA.
- Williamson, S.R., et al. (2019) ‘Novel and Emerging Entities in Renal Neoplasia: An Update from the 2018 Genitourinary Pathology Society (GUPS) Annual Meeting’, Advances in Anatomic Pathology, 26(2), pp. 115–126. doi:10.1097/PAP.0000000000000217.